A panel of European drug reviewers notified Biogen that its Alzheimer’s treatment Aduhelm is unlikely to win approval there, the company announced Wednesday.
Aduhelm received a “negative trend vote” from experts at the European Medicines Agency, following a type of hearing called an oral explanation.
Create a display name to comment
This name will appear with your comment
